Results 81 to 90 of about 100,614 (290)

Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study) [PDF]

, 2022
Tomohisa Yamamoto, Tsutomu Fujii, Satoshi Hirano, Fuyuhiko Motoi, Goro Honda, Kenichiro Uemura, Joji Kitayama, Michiaki Unno, Yasuhiro Kodera, Hiroki Yamaue, Toshio Shimokawa, Daisuke Hashimoto, So Yamaki, Hideyuki Yoshitomi, Fumihiko Miura, Hideki Ueno, Mitsugu Sekimoto, Sohei Satoi, on behalf of the Study Group of Pancreatic Ductal Adenocarcinoma with Peritoneal Metastasis   +18 more
openalex   +1 more source

Prognostic Significance of Portal Vein Tumor Thrombus in Pancreatic Ductal Adenocarcinoma Treated With Chemoradiotherapy

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim To examine the significance of portal vein tumor thrombus (PVTT) as a prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC) treated with chemoradiotherapy (CRT) followed by surgery. Methods The study retrospectively examined 313 patients with borderline resectable (BR) or locally advanced (LA) PDAC who underwent CRT ...
Aoi Hayasaki, Motonori Nagata, Miki Usui, Hiroshi Imai, Yusuke Iizawa, Akihiro Tanemura, Yasuhiro Murata, Naohisa Kuriyama, Masashi Kishiwada, Shugo Mizuno   +9 more
wiley   +1 more source

CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.

PLoS ONE
Gemcitabine is commonly used in the standard first-line treatment of urothelial carcinoma (UC); however, the emergence of drug resistance significantly limits its clinical benefit.
Kun-Lin Hsieh, Kuan-Hua Huang, Ching-Ping Chang, Hung-Wen Tsai, Yu-Hao Chang, Yi-Ru Zheng, Huei-Sheng Huang   +6 more
doaj   +1 more source

Repositioning of Old Drugs for Novel Cancer Therapies: Continuous Therapeutic Perfusion of Aspirin and Oseltamivir Phosphate with Gemcitabine Treatment Disables Tumor Progression, Chemoresistance, and Metastases [PDF]

, 2022
Bessi Qorri, Reza Bayat Mokhtari, William Harless, Myron R. Szewczuk   +3 more
openalex   +1 more source

Bioinformatics‐based discovery of the involvement of PSAT1 in mediating the anti‐lung adenocarcinoma activity of triptolide

Animal Models and Experimental Medicine, EarlyView.
Transcriptome sequencing was performed on tumor tissues from triptolide‐treated tumor‐bearing mice. The sequencing results were integrated with data from public databases for comprehensive analysis, and potential regulatory targets of triptolide were identified.
Zhiwen Cao, Lulu Zhang, Wenqiang Zhang, Rong Wan, Xiaogang Peng, Jinyan Xie, Ruru Bai, Jiejing Jin, Changqi Shi, Lan Yan, Xiangyu Guo, Yang Shen, Cheng Lu   +12 more
wiley   +1 more source

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer

Computational and Structural Biotechnology Journal
Gemcitabine is a standard first-line drug for pancreatic cancer chemotherapy. Nevertheless, gemcitabine resistance is common and significantly limits its therapeutic efficacy, impeding advancements in pancreatic cancer treatment. In this study, through a
Saimeng Shi, Longyun Ye, Kaizhou Jin, Xianjun Yu, Duancheng Guo, Weiding Wu   +5 more
doaj   +1 more source

3D Hydrogel Cell Cultures and Their Biomedical Applications

Advanced NanoBiomed Research, EarlyView.
The review highlights the advantages of hydrogel‐based 3D cell cultures over traditional 2D models. These hydrogels closely mimic natural cellular environments, improving research in tissue engineering, drug discovery, cancer studies, and neuroscience.
Tri Lan Thai, Arushi Manchanda, Sarah L. Higginbottom, Estrella Sanz Rodriguez, Richard Wilson, Eva Tomaskovic‐Crook, Jeremy M. Crook, Brett Paull   +7 more
wiley   +1 more source

Surface‐Coated Inorganic Nanomaterials for Drug Delivery: Chemical Design, Biomedical Applications, and Mechanistic Insights

Advanced NanoBiomed Research, EarlyView.
This review explores how surface‐coated inorganic nanomaterials are chemically engineered for advanced drug delivery. It highlights design principles, coating strategies, and biomedical applications, emphasizing how surface chemistry governs biocompatibility, targeting, and controlled release.
Hossein Daneshgar, Sepideh Ahmadi, Nikzad Abbariki, Navid Rabiee, Sidi A. Bencherif   +4 more
wiley   +1 more source

Engineering Tertiary Lymphoid Structures: Nanomedicine, Bioengineering, and Biomaterials for Precision Immunotherapy

Advanced NanoBiomed Research, EarlyView.
This review explains how biomaterials and nanoparticles can be used to induce or modulate tertiary lymphoid structures (TLSs), which are ectopic immune hubs that form in nonlymphoid tissues during chronic disease and cancer. By comparing different methods, the article highlights design principles for modeling TLSs or recapitulating specific TLS ...
Shaza Karaman, Mei ElGindi, Jeremy Teo
wiley   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source